Clinical trials: Metastatic Colorectal Cancer (mCRC)

NSCLC, Metastatic Colorectal Carcinoma

Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)

• Completed
• Age: 18 years and older
• Phase 2
• Results posted

The primary goal of this trial is to assess clinical response to nivolumab and pixatimod, and, nivolumab, pixatimod and cyclophosphamide in three separate patient cohorts.

Conditions

NSCLC, Metastatic Colorectal Carcinoma, Refractory Melanoma

Trial name

NCT05061017

Testing

Pixatimod, Nivolumab, Cyclophosphamide (low dose)

Where

United States

Volunteers

13 people

Sponsor

Diwakar Davar